Subscribe to our newsletter

Studies: Biologic Proves Worth as Monotherapy in RA

CorEvitas is now part of Thermo Fisher Scientific. Read More.

by Ed Susman, Contributing Writer, MedPage Today

ORLANDO — Rheumatoid arthritis (RA) patients who received tocilizumab (Actemra) with methotrexate achieved low disease activity and could discontinue methotrexate while maintaining disease control, researchers said here.

In a study designed to evaluate whether tocilizumab monotherapy was non-inferior to the combination, patients who achieved a DAS28-ESR (Disease Activity Score) of 3.2 or lower at week 24 were eligible for the trial to determine if they could safely discontinue methotrexate, according to Joel Kremer, MD, of Albany Medical College and The Center for Rheumatology in Albany, N.Y., and colleagues in a presentation at the Rheumatology Nurses Society annual meeting.

Read More…